Percutaneous Coronary Intervention Pharmacology. From a Triangle to a Square**Editorials published in the Journal of American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 51, Issue 7, 2008, Pages 698-700

  Dauerman, Harold L ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLACEBO; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; WARFARIN;

BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CORONARY STENT; DISEASE MARKER; EDITORIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; Q WAVE; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PROGNOSIS; RISK ASSESSMENT; STENTS;

EID: 38949108302     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.10.042     Document Type: Editorial

References (19)

1. Ndrepepa G., Berger P.B., Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
2. Feit F., Voeltz M.D., Attubato M., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 100 (2007) 1364-1369
3. Ellis S.G., Bhatt D., Kapadia S., Lee D., Yen M., and Whitlow P.L. Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. Catheter Cardiovasc Interv 67 (2006) 541-545
4. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
5. Manoukian S.V., Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49 (2007) 1362-1368
6. Jozic J., Steinhubl S.R., Dangas G.D., Hooper W.C., and Stone G.W. Markers of inflammation and their changes over time in relationship to clinical outcomes and therapeutic interventions in the acute coronary syndrome patient: results from the ACUITY inflammation sub-study. Am J Cardiol 98 (2006) 36M
7. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
8. Rao S.V., Jollis J.G., Harrington R.A., et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292 (2004) 1555-1562
9. Jeremias A., Baim D.S., Ho K.K., et al. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol 44 (2004) 1210-1214
10. Steinhubl S.R., Kastrati A., and Berger P.B. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 154 (2007) 3-11
11. Rao S.V., O'Grady K., Pieper K.S., et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47 (2006) 809-816
12. Serebruany V.L., and Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol 99 (2007) 288-290
13. Waksman R. ACUITY-PCI: one drug does not fit all. Lancet 369 (2007) 881-882
14. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
15. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998) 1665-1671
16. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
17. Dauerman H.L., Goldberg R.J., White K., et al. Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 90 (2002) 838-842
18. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
19. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682